176 related articles for article (PubMed ID: 27422302)
1. SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
Kim JH; Lee C; Cheong HS; Koh Y; Ahn KS; Kim HL; Shin HD; Yoon SS
Cancer Chemother Pharmacol; 2016 Sep; 78(3):533-40. PubMed ID: 27422302
[TBL] [Abstract][Full Text] [Related]
2. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.
Wan H; Zhu J; Chen F; Xiao F; Huang H; Han X; Zhong L; Zhong H; Xu L; Ni B; Zhong J
J Exp Clin Cancer Res; 2014 Nov; 33(1):90. PubMed ID: 25398670
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia].
Wang D; Ke XY; Wang J; Xu F; Hu YF
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1384-8. PubMed ID: 17785057
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
5. NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.
Cheong HS; Koh Y; Ahn KS; Lee C; Shin HD; Yoon SS
Pharmacogenet Genomics; 2014 Sep; 24(9):436-41. PubMed ID: 25000516
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
Amaki J; Onizuka M; Ohmachi K; Aoyama Y; Hara R; Ichiki A; Kawai H; Sato A; Miyamoto M; Toyosaki M; Machida S; Kojima M; Shirasugi Y; Kawada H; Ogawa Y; Ando K
Int J Hematol; 2015 Jun; 101(6):543-53. PubMed ID: 25735499
[TBL] [Abstract][Full Text] [Related]
7. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.
Cai J; Damaraju VL; Groulx N; Mowles D; Peng Y; Robins MJ; Cass CE; Gros P
Cancer Res; 2008 Apr; 68(7):2349-57. PubMed ID: 18381442
[TBL] [Abstract][Full Text] [Related]
8. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
[TBL] [Abstract][Full Text] [Related]
10. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.
Kim KI; Huh IS; Kim IW; Park T; Ahn KS; Yoon SS; Yoon JH; Oh JM
Eur J Cancer; 2013 Jan; 49(2):403-10. PubMed ID: 22964418
[TBL] [Abstract][Full Text] [Related]
11. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
[TBL] [Abstract][Full Text] [Related]
12. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
[TBL] [Abstract][Full Text] [Related]
13. Genetic Association of PARP15 Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population.
Lee MK; Cheong HS; Koh Y; Ahn KS; Yoon SS; Shin HD
Genet Test Mol Biomarkers; 2016 Nov; 20(11):696-701. PubMed ID: 27610459
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis.
Macanas-Pirard P; Leisewitz A; Broekhuizen R; Cautivo K; Barriga FM; Leisewitz F; Gidi V; Riquelme E; Montecinos VP; Swett P; Besa P; Ramirez P; Ocqueteau M; Kalergis AM; Holt M; Rettig M; DiPersio JF; Nervi B
PLoS One; 2012; 7(5):e37203. PubMed ID: 22629369
[TBL] [Abstract][Full Text] [Related]
16. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
18. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
Milazzo L; Peri AM; Mazzali C; Magni C; Calvi E; De Nicolò A; Clementi E; Cheli S; D'Avolio A; Antinori S; Falvella FS
J Antimicrob Chemother; 2015 Apr; 70(4):1155-60. PubMed ID: 25583751
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine.
Visser N; Lourens HJ; Huls G; Bremer E; Wiersma VR
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33652766
[TBL] [Abstract][Full Text] [Related]
20. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]